arrow_back Back Filing freshness 10-K FY 2026 SEC EDGAR

download Export Data

BriaCell Therapeutics Corp.

BCTX

$3.30 ▲ +0.09 (+2.80%) at close

7 Visible periods

20 Metrics

Absolute Benchmarks

Price Chart

Health

Weak

Bearish Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, BriaCell Therapeutics Corp. shows weak fundamentals, weighed down by FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $16.5M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC None

FCF / Share $-5.74 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-34.90M

↓ -32.7% —

FCF / Share Free cash flow per share

$-5.74

↑ +91.4% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

FCF / Net IncomeFCF / Net Income of 0.82x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2026 Jul 31, 2026 10-K ↗	FY 2025 Jul 31, 2025 10-K ↗	FY 2024 Jul 31, 2024 10-K ↗	FY 2023 Jul 31, 2023 10-K ↗	FY 2022 Jul 31, 2022 10-K ↗	FY 2021 Jul 31, 2021 10-K ↗	FY 2020 Jul 31, 2020 10-K ↗
EPS Growth YoY (%)	88.8% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-42.4% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-3260.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	24.9% Good Good Year-over-year change in earnings per share Optimal: > 10%	43.5% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-32.7% Weak ↑ Weak Improving Year-over-year change in net income	-449.1% Weak ↓ Weak Declining Year-over-year change in net income	76.4% Excellent ↑ Excellent Improving Year-over-year change in net income	24.4% Good Good Year-over-year change in net income	-94.3% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	91.4% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	70.3% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-14641.2% Weak ↓ Weak Declining Year-over-year change in free cash flow	-88.7% Weak Weak Year-over-year change in free cash flow	53.0% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2026 Jul 31, 2026 10-K ↗	FY 2025 Jul 31, 2025 10-K ↗	FY 2024 Jul 31, 2024 10-K ↗	FY 2023 Jul 31, 2023 10-K ↗	FY 2022 Jul 31, 2022 10-K ↗	FY 2021 Jul 31, 2021 10-K ↗	FY 2020 Jul 31, 2020 10-K ↗
Effective Tax Rate (%) (%)	—	—	—	—	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
FCF / Net Income (x)	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.07x Fair ↓ Fair Declining Free cash flow relative to reported net income Optimal: > 1x	5.13x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	1.17x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.47x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.56x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2026 Jul 31, 2026 10-K ↗	FY 2025 Jul 31, 2025 10-K ↗	FY 2024 Jul 31, 2024 10-K ↗	FY 2023 Jul 31, 2023 10-K ↗	FY 2022 Jul 31, 2022 10-K ↗	FY 2021 Jul 31, 2021 10-K ↗	FY 2020 Jul 31, 2020 10-K ↗
Return on Invested Capital (%)	—	—	—	—	-148.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-25.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-152.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-125.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-567.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-85.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-35.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-12.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	—	—	—	—	-259.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1832%)	-49.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-433%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2026 Jul 31, 2026 10-K ↗	FY 2025 Jul 31, 2025 10-K ↗	FY 2024 Jul 31, 2024 10-K ↗	FY 2023 Jul 31, 2023 10-K ↗	FY 2022 Jul 31, 2022 10-K ↗	FY 2021 Jul 31, 2021 10-K ↗	FY 2020 Jul 31, 2020 10-K ↗
Interest Coverage (x)	—	—	—	—	-15616.90x Weak Weak Operating income divided by interest expense Optimal: > 5x	-88.81x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-9.85M	$-10.49M	$-862.09K	$-21.25M	$-41.04M	$-57.27M	—

📊 What does each share earn? 5 metrics

Metric	FY 2026 Jul 31, 2026 10-K ↗	FY 2025 Jul 31, 2025 10-K ↗	FY 2024 Jul 31, 2024 10-K ↗	FY 2023 Jul 31, 2023 10-K ↗	FY 2022 Jul 31, 2022 10-K ↗	FY 2021 Jul 31, 2021 10-K ↗	FY 2020 Jul 31, 2020 10-K ↗
Basic EPS, GAAP (USD)	$-6.97	$-62.19	$-43.68	$-1.30	$-1.73	$-3.06	—
Free Cash Flow per Share (USD)	$-5.74	$-66.58	$-224.09	$-1.52	$-0.81	$-1.71	—
Book Value per Share (USD)	—	—	—	—	$0.67	$1.81	—
Tangible Book Value per Share (USD)	—	—	—	—	$0.67	$1.81	—
Basic Weighted Avg Shares (shares)	5.01M	423,114	109,699	15.62M	15.49M	4.52M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2026 Jul 31, 2026 10-K ↗	FY 2025 Jul 31, 2025 10-K ↗	FY 2024 Jul 31, 2024 10-K ↗	FY 2023 Jul 31, 2023 10-K ↗	FY 2022 Jul 31, 2022 10-K ↗	FY 2021 Jul 31, 2021 10-K ↗	FY 2020 Jul 31, 2020 10-K ↗
Working Capital (USD)	$14.06M	$15.95M	$-3.81M	$25.15M	$41.41M	$57.24M	—
Total Equity (USD)	—	—	—	—	$10.33M	$27.67M	$-2.74M

📋 What is driving earnings? 3 metrics

Metric	FY 2026 Jul 31, 2026 10-K ↗	FY 2025 Jul 31, 2025 10-K ↗	FY 2024 Jul 31, 2024 10-K ↗	FY 2023 Jul 31, 2023 10-K ↗	FY 2022 Jul 31, 2022 10-K ↗	FY 2021 Jul 31, 2021 10-K ↗	FY 2020 Jul 31, 2020 10-K ↗
Depreciation Expense (USD)	$104.06K	$91.36K	$68.63K	—	$15.27K	$15.26K	—
Net Income, GAAP (USD)	$-34.90M	$-26.31M	$-4.79M	$-20.30M	$-26.84M	$-13.82M	—
Operating Cash Flow (USD)	$-28.65M	$-28.17M	$-24.13M	$-23.74M	$-12.48M	$-7.75M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 22 quarters

BriaCell Therapeutics Corp.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare BCTX with peers